oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2026-25-4-135-144oncotomsk-4428Research ArticleОБЗОРЫREVIEWSСовременные тенденции в области применения абиратерона. Обзор клинических и экспериментальных работModern trends in the use of abiraterone. A review of clinical and experimental researchhttps://orcid.org/0009-0009-4946-6067УрюпинаА. А.UryupinaA. A.

Урюпина Анастасия Александровна - хирург хирургического отделения, ГБУ РО «Городская больница № 6»; соискатель ученой степени, ФГБОУ ВО «РостГМУ» Минздрава России.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

Anastasia A. Uryupina - MD, Surgeon, Surgery Department, City Hospital No. 6; Rostov State Medical University.

29, Nakhichevansky Lane, Rostov-on-Don, 344022

https://orcid.org/0009-0005-6238-7874ПетькоВ. С.PetkoV. S.

Петько Вера Сергеевна - студентка 6-го курса.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

Vera S. Petko - 6th year student, Rostov State Medical University.

29, Nakhichevansky Lane, Rostov-on-Don, 344022

https://orcid.org/0000-0002-8538-5856КрюкТ. В.KriukT. V.

Крюк Татьяна Владленовна - кандидат химических наук, доцент, старший научный сотрудник.

283048, Донецкая народная республика, Донецк, ул. Розы Люксембург, 70

Tatyana V. Kriuk - PhD, Associate Professor, Senior Researcher, L.M. Litvinenko Institute of Physical-Organic Chemistry and Coal Chemistry.

70, R. Luxemburg St., Donetsk, 283048, Donetsk People’s Republic

https://orcid.org/0009-0000-9237-6512ГюльмамедовД. Н.GyulmamedovD. N.

Гюльмамедов Давид Натигович - студент 6-го курса.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

David N. Gyulmamedov - 6th year student, Rostov State Medical University.

29, Nakhichevansky Lane, Rostov-on-Don, 344022

https://orcid.org/0009-0007-9050-3582ИорданидиТ. А.IordanidiT. A.

Иорданиди Татьяна Александровна - студентка 6-го курса.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

Tatiana A. Iordanidi - 6th year student, Rostov State Medical University.

29, Nakhichevansky Lane, Rostov-on-Don, 344022

https://orcid.org/0000-0003-3104-827XДодоховаМ. А.DodokhovaM. A.

Додохова Маргарита Авдеевна - доктор медицинских наук, доцент, профессор кафедры патологической физиологии, ФГБОУ ВО «РостГМУ» Минздрава России; старший научный сотрудник отдела исследований радикальных реакций, ФГБНУ «Институт физико-органической химии и углехимии им. Л.М. Литвиненко».

344022, Ростов-на-Дону, пер. Нахичеванский, 29; 283048, Донецкая народная республика, Донецк, ул. Розы Люксембург, 70

Author ID (Scopus) 55623105600

Margarita A. Dodokhova - MD, DSc, Associate Professor, Professor, Department of Pathological Physiology, Rostov State Medical University; Senior Researcher, Department of Radical Reactions Research, L.M. Litvinenko Institute of Physical-Organic Chemistry and Coal Chemistry.

29, Nakhichevansky Lane, Rostov-On-Don, 344022; 70, R. Luxemburg St., Donetsk, 283048, Donetsk People’s Republic

Author ID (Scopus) 55623105600

dodohova@mail.ruhttps://orcid.org/0000-0002-2796-9466ПоповаИ. М.PopovaI. M.

Попова Инга Мовлиевна - доктор медицинских наук, профессор, заведующая кафедрой патологической физиологии.

344022, Ростов-на-Дону, пер. Нахичеванский, 29

Author ID (Scopus) 56300093600

Inga M. Popova - MD, DSc, Professor, Head of the Department of Pathological Physiology, Rostov State Medical University.

29, Nakhichevansky Lane, Rostov-on-Don, 344022

Author ID (Scopus) 56300093600

ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical UniversityRussian FederationФГБНУ «Институт физико-органической химии и углехимии им. Л.М. Литвиненко»РоссияL.M. Litvinenko Institute of Physical-Organic Chemistry and Coal ChemistryRussian FederationФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России; ФГБНУ «Институт физико-органической химии и углехимии им. Л.М. Литвиненко»РоссияRostov State Medical University; L.M. Litvinenko Institute of Physical-Organic Chemistry and Coal ChemistryRussian Federation202621092026254135144Copyright © Урюпина А.А., Петько В.С., Крюк Т.В., Гюльмамедов Д.Н., Иорданиди Т.А., Додохова М.А., Попова И.М., 20262026Урюпина А.А., Петько В.С., Крюк Т.В., Гюльмамедов Д.Н., Иорданиди Т.А., Додохова М.А., Попова И.М.Uryupina A.A., Petko V.S., Kriuk T.V., Gyulmamedov D.N., Iordanidi T.A., Dodokhova M.A., Popova I.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/4428

Цель исследования – обобщение современных тенденций в области стратегий применения абиратерона при лечении рака простаты на основе клинических и экспериментальных исследований. Материал и методы. Проведен поиск публикаций в базах данных MedLine, Scopus, WoS и РИНЦ за последние 10 лет. Проанализирована информация о фармацевтических, экспериментальных и клинических исследованиях, посвященных современным тенденциям в области стратегий применения абиратерона при лечении рака простаты. Из 121 найденного источника 54 включено в обзор. Результаты. Для терапии как гормончувствительного рака предстательной железы (РПЖ), так и его кастрационно-резистентной формы активно исследуются препараты абиратерона. Применение лекарственных средств на основе абиратерона (ЛС-AB) или необратимых блокаторов андрогеновых рецепторов приводит к длительному контролю заболевания и улучшению результатов лечения больных РПЖ. Регулирование уровня тестостерона между кастрационным и сверхфизиологическим уровнями подавляет рост раковых клеток (биполярная андрогенная терапия). Значительные ограничения применения ЛС-AB связаны с побочным действием данной группы препаратов: изменение водно-электролитного баланса, вызванного влиянием на уровень минералокортикоидов в крови, реже – развитие относительной или абсолютной печеночной и почечной недостаточности. Для снижения дозы и/или повышения биодоступности препарата применяются два основных подхода – использование положительного эффекта пищи для увеличения экспозиции и разработка супердженериков. Современными стратегиями преодоления собственно резистентности к депривационной и химиотерапии являются: применение комбинированной терапии с использованием агентов с различным механизмом реализации фармакологической активности, их метрономного режима введения, а также разработка новых модифицированных противоопухолевых агентов, сочетающих в одной молекуле цитотоксический и антиандрогенный компоненты. На основе оловоорганических соединений получены фармакологически активные соединения абиратерона двойного (мультимодального) действия, активно индуцирующие апоптоз и блокирующие пролиферацию в фазе G2/M клеточного цикла (исследования in vitro). Заключение. Комбинацию этих подходов в перспективе можно использовать для персонализированного лечения гормонально-активных злокачественных новообразований различных локализаций (предстательная железа, молочная железа и др.).

Objective: to summarize current trends in the use of abiraterone in the treatment of prostate cancer based on clinical and experimental studies. Material and Methods. We searched and analyzed information in MedLine, Scopus, WoS, and the Russian Science Citation Index (RSCI) databases for the past 10 years. We analyzed information on pharmaceutical, experimental, and clinical studies on current trends in abiraterone use strategies for prostate cancer treatment, based on clinical and experimental studies. Results. Abiraterone-based therapies are being actively studied for the treatment of both hormone-sensitive and castration-resistant prostate cancer. The use of abiraterone-based therapies or irreversible androgen receptor blockers leads to long-term disease control and improved treatment outcomes for prostate cancer patients. Regulation of testosterone levels between castration and supraphysiological levels suppresses the growth of cancer cells (bipolar androgen therapy). Significant limitations in the use of abiraterone-based therapies are associated with their side effects: changes in water-electrolyte balance due to the effect on the level of mineralocorticoids in the blood, and the development of relative or absolute liver and kidney failure. To reduce the dose and/or increase the bioavailability of the drug, two main approaches are used: using the positive effect of food to increase exposure and the development of supergenerics. Current strategies for overcoming resistance to deprivation and chemotherapy include combination therapy using agents with different mechanisms of pharmacological activity, metronomic administration, and the development of new modified antitumor agents that combine a cytotoxic and antiandrogenic component in a single molecule. Pharmacologically active compounds, such as abiraterone, have been developed using organotin compounds, offering dual (multimodal) action and actively inducing apoptosis and inhibiting proliferation in the G2/M phase of the cell cycle (in vitro studies). Conclusion. The combination of these approaches has the potential to be used for personalized treatment of hormonally active malignant tumors in various locations (prostate, breast, etc.).

абиратеронрак предстательной железыантипролиферативная активностьметрономный режимкомбинированное введениемодифицированные оловоорганические соединенияabirateroneprostate cancerantiproliferative activitymetronomic chemotherapycombined administrationmodified organotin compoundsТема FRES-2026-0012 «Механохимическая модификация гуминовых веществ и полисахаридов; исследование полученных на их основе гидрогелей, матричных форм биологически активных веществ, новых видов ПАВ, других практически полезных продуктов».FRES-2026-0012 “Mechanochemical modification of humic substances and polysaccharides; research of hydrogels obtained on their basis, matrix forms of biologically active substances, new types of surfactants, and other practically useful products”.ReferencesЗлокачественные новообразования в России в 2024 году (заболеваемость). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой, Н.Ю. Золотарева. М., 2025. 178 с. ISBN: 9785-85502-311-4.Malignant tumors in Russia in 2024 (morbidity). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova, N.Yu. Zolotarev. Moscow, 2025; 178 p. (in Russian). ISBN: 9785-85502-311-4.Mar N., Dwabe S., Baranda M.N., Zarrabi K.K., Eturi A., Gulati S., Parikh M., Seyedin S.N., Kalebasty A.R. Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2024; Apr. 22(2): 217-23. doi: 10.1016/j.clgc.2023.11.002.Mar N., Dwabe S., Baranda M.N., Zarrabi K.K., Eturi A., Gulati S., Parikh M., Seyedin S.N., Kalebasty A.R. Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2024; Apr. 22(2): 217-23. doi: 10.1016/j.clgc.2023.11.002.Potocki P.M., Wysocki P.J. Evolution of prostate cancer therapy. Part 1. Oncol Clin Pract. 2022; 18(3): 177-88. doi: 10.5603/OCP.2021.0001.Potocki P.M., Wysocki P.J. Evolution of prostate cancer therapy. Part 1. Oncol Clin Pract. 2022; 18(3): 177-88. doi: 10.5603/OCP.2021.0001.Ковченко Г.А., Сивков А.В., Любченко Л.Н., Каприн А.Д. Эпигенетические нарушения и нейроэндокринная дифференцировка при раке предстательной железы. Сибирский онкологический журнал. 2025; 24(1): 115-24. doi: 10.21294/1814-4861-2025-24-1-115-124. EDN: EBMTCMKovchenko G.A., Sivkov A.V., Lyubchenko L.N., Kaprin A.D. Epigenetic abnormalities and neuroendocrine differentiation in prostate cancer. Siberian Journal of Oncology. 2025; 24(1): 115-24. (in Russian). doi: 10.21294/1814-4861-2025-24-1-115-124. EDN: EBMTCMKneev A.Y., Shkol'nik M.I., Bogomolov O.A., Zharinov G.M. Prostate specific antigen density as a prognostic factor in patients with prostate cancer treated with combined hormonal radiation therapy. Siberian Journal of Oncology. 2022; 21(3): 12-23 (in English). doi: 10.21294/1814-48612022-21-3-12-23. EDN: WYUTEU.Kneev A.Y., Shkol'nik M.I., Bogomolov O.A., Zharinov G.M. Prostate specific antigen density as a prognostic factor in patients with prostate cancer treated with combined hormonal radiation therapy. Siberian Journal of Oncology. 2022; 21(3): 12-23 (in English). doi: 10.21294/1814-48612022-21-3-12-23. EDN: WYUTEU.Mitra Ghosh T., Mazumder S., Davis J., Yadav J., Akinpelu A., Alnaim A., Kumar H., Waliagha R., Church Bird A.E., Rais-Bahrami S., Bird R.C., Mistriotis P., Mishra A., Yates C.C., Mitra A.K., Arnold R.D. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. Cancer Res Commun. 2023; 3(7): 1286-311. doi: 10.1158/2767-9764.CRC-22-0427.Mitra Ghosh T., Mazumder S., Davis J., Yadav J., Akinpelu A., Alnaim A., Kumar H., Waliagha R., Church Bird A.E., Rais-Bahrami S., Bird R.C., Mistriotis P., Mishra A., Yates C.C., Mitra A.K., Arnold R.D. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. Cancer Res Commun. 2023; 3(7): 1286-311. doi: 10.1158/2767-9764.CRC-22-0427.Wysocki P.J., Lubas M.T., Wysocka M.L. Metronomic Chemotherapy in Prostate Cancer. J Clin Med. 2022; 11(10): 2853. doi: 10.3390/jcm11102853.Wysocki P.J., Lubas M.T., Wysocka M.L. Metronomic Chemotherapy in Prostate Cancer. J Clin Med. 2022; 11(10): 2853. doi: 10.3390/jcm11102853.Li Z., Alyamani M., Li J., Rogacki K., Abazeed M., Upadhyay S.K., Balk S.P., Taplin M.E., Auchus R.J., Sharifi N. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016; 533(7604): 547-51. doi: 10.1038/nature17954.Li Z., Alyamani M., Li J., Rogacki K., Abazeed M., Upadhyay S.K., Balk S.P., Taplin M.E., Auchus R.J., Sharifi N. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016; 533(7604): 547-51. doi: 10.1038/nature17954.Saad F., Efstathiou E., Attard G., Flaig T.W., Franke F., Goodman O.B., Oudard S., Steuber T., Suzuki H., Wu, D., Yeruva K., De Porre P., Brookman-May S., Li S., Li J., Thomas S., Bevans K.B., Mundle S.D., McCarthy S.A., Rathkopf D.E., ACIS Investigators. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): A randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021; 22(11): 1541-59. doi: 10.1016/S1470-2045-(21)00402-2.Saad F., Efstathiou E., Attard G., Flaig T.W., Franke F., Goodman O.B., Oudard S., Steuber T., Suzuki H., Wu, D., Yeruva K., De Porre P., Brookman-May S., Li S., Li J., Thomas S., Bevans K.B., Mundle S.D., McCarthy S.A., Rathkopf D.E., ACIS Investigators. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): A randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021; 22(11): 1541-59. doi: 10.1016/S1470-2045-(21)00402-2.Носов Д.А., Волкова М.И., Гладков О.А., Карабина Е.В., Крылов В.В., Матвеев В.Б., Усычкин С.В., Митин Т. Рак предстательной железы. Злокачественные опухоли. 2023; 13(3S2-1): 640-60. doi: 10.18027/2224-5057-2023-13-3s2-1-640-660. EDN: DDPNET.Nosov D.A., Volkova M.I., Gladkov O.A., Karabina E.V., Krylov V.V., Matveev V.B., Usychkin S.V., Mitin T. Prostate cancer. Malignant Tumours. 2023; 13(3S2-1): 640-60. (in Russian). doi: 10.18027/2224-5057-2023-13-3s2-1-640-660. EDN: DDPNET.Danielak D., Krejci T., Beranek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. 2022; 176: 106254. doi: 10.1016/j.ejps.2022.106254.Danielak D., Krejci T., Beranek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. 2022; 176: 106254. doi: 10.1016/j.ejps.2022.106254.Raychaudhuri R., Lin D.W., Montgomery R.B. Prostate Cancer: A Review. JAMA. 2025; 333(16): 1433-46. doi:10.1001/jama.2025.0228.Raychaudhuri R., Lin D.W., Montgomery R.B. Prostate Cancer: A Review. JAMA. 2025; 333(16): 1433-46. doi:10.1001/jama.2025.0228.Aggarwal R., Huang J., Alumkal J.J., Zhang L., Feng F.Y., Thomas G.V., Weinstein A.S., Friedl V., Zhang C., Witte O.N., Lloyd P., Gleave M., Evans C.P., Youngren J., Beer T.M., Rettig M., Wong C.K., True L., Foye A., Playdle D., Ryan C.J., Lara P., Chi K.N., Uzunangelov V., Sokolov A., Newton Y., Beltran H., Demichelis F., Rubin M.A., Stuart J.M., Small E.J. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018; 36(24): 2492-503. doi: 10.1200/JCO.2017.77.6880.Aggarwal R., Huang J., Alumkal J.J., Zhang L., Feng F.Y., Thomas G.V., Weinstein A.S., Friedl V., Zhang C., Witte O.N., Lloyd P., Gleave M., Evans C.P., Youngren J., Beer T.M., Rettig M., Wong C.K., True L., Foye A., Playdle D., Ryan C.J., Lara P., Chi K.N., Uzunangelov V., Sokolov A., Newton Y., Beltran H., Demichelis F., Rubin M.A., Stuart J.M., Small E.J. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018; 36(24): 2492-503. doi: 10.1200/JCO.2017.77.6880.Humeniuk M.S., Gupta R.T., Healy P., McNamara M., Ramalingam S., Harrison M., George D., Zhang T., Wu Y., Armstrong A.J. Platinum sensitivity in metastatic prostate cancer: Does histology matter? Prostate Cancer Prostatic Dis. 2018; 21(1): 92-99. doi: 10.1038/s41391-017-0017-6.Humeniuk M.S., Gupta R.T., Healy P., McNamara M., Ramalingam S., Harrison M., George D., Zhang T., Wu Y., Armstrong A.J. Platinum sensitivity in metastatic prostate cancer: Does histology matter? Prostate Cancer Prostatic Dis. 2018; 21(1): 92-99. doi: 10.1038/s41391-017-0017-6.Chen M.K., Liang Z.J., Luo D.S., Xue K.Y., Liao D.Y., Li Z., Yu Y., Chen Z.S., Zhao S.C. Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy? Front Pharmacol. 2022; 13: 843110. doi: 10.3389/fphar.2022.843110.Chen M.K., Liang Z.J., Luo D.S., Xue K.Y., Liao D.Y., Li Z., Yu Y., Chen Z.S., Zhao S.C. Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy? Front Pharmacol. 2022; 13: 843110. doi: 10.3389/fphar.2022.843110.Saad F., Clarke N.W., Oya M., Shore N., Procopio G., Guedes J.D., Arslan C., Mehra N., Parnis F., Brown E., Schltirmann F., Joung J.Y., Sugimoto M., Sartor O., Liu Y.Z., Poehlein C., Barker L., Del Rosario P.M., Armstrong A.J. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24(10): 1094-1108. doi: 10.1016/S1470-2045(23)00382-0.Saad F., Clarke N.W., Oya M., Shore N., Procopio G., Guedes J.D., Arslan C., Mehra N., Parnis F., Brown E., Schltirmann F., Joung J.Y., Sugimoto M., Sartor O., Liu Y.Z., Poehlein C., Barker L., Del Rosario P.M., Armstrong A.J. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023; 24(10): 1094-1108. doi: 10.1016/S1470-2045(23)00382-0.Clarke N.W., Armstrong A.J., Thiery-Vuillemin A., Oya M., Shore N., Loredo E., Procopio G., de Menezes J., Girotto G., Arslan C., Mehra N., Parnis F., Brown E., Schltirmann F., Joung J.Y., Sugimoto M., Virizuela J.A., Emmenegger U., Navratil J., Buchschacher G.L., Poehlein C., Harrington E.A., Desai C., Kang J., Saad F. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022; 1(9): EVIDoa2200043. doi: 10.1056/EVIDoa2200043.Clarke N.W., Armstrong A.J., Thiery-Vuillemin A., Oya M., Shore N., Loredo E., Procopio G., de Menezes J., Girotto G., Arslan C., Mehra N., Parnis F., Brown E., Schltirmann F., Joung J.Y., Sugimoto M., Virizuela J.A., Emmenegger U., Navratil J., Buchschacher G.L., Poehlein C., Harrington E.A., Desai C., Kang J., Saad F. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022; 1(9): EVIDoa2200043. doi: 10.1056/EVIDoa2200043.Roberts H.N., Maurice-Dror C., Chi K.N. Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer. Future Oncol. 2025; 21(2): 201-11. doi: 10.1080/14796694.2024.2442900.Roberts H.N., Maurice-Dror C., Chi K.N. Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer. Future Oncol. 2025; 21(2): 201-11. doi: 10.1080/14796694.2024.2442900.de Bono J.S., He M., Shi Z., Nowicka M., Bracarda S., Sternberg C.N., Chi K.N., Olmos D., Sandhu S., Massard C., Matsubara N., Chen G., Bienz N.S., Canter D., Wongchenko M., Sweeney C. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025; 87(6): 672-82. doi: 10.1016/j.eururo.2024.12.015.de Bono J.S., He M., Shi Z., Nowicka M., Bracarda S., Sternberg C.N., Chi K.N., Olmos D., Sandhu S., Massard C., Matsubara N., Chen G., Bienz N.S., Canter D., Wongchenko M., Sweeney C. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025; 87(6): 672-82. doi: 10.1016/j.eururo.2024.12.015.Smith M., Piulats J., Todenhofer T., Lee J.L., Arija J.A., Mazilu L., Azad A., Alonso-Gordoa T., McGovern U., Choudhury A., Horvath L., Ye D., Han W., Suzuki H., Uemura H., McKay R., Ades S., Flechon A., Pieczonka C., Fernandes M.S., Hulstijn M., Lithio A., Nacerddine K., Agarwal N., CYCLONE 2 investigators. Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2025; 26(11): 1489-1500. doi: 10.1016/S1470-2045(25)00475-9.Smith M., Piulats J., Todenhofer T., Lee J.L.,Arija J.A., Mazilu L., Azad A., Alonso-Gordoa T., McGovern U., Choudhury A., Horvath L., Ye D., Han W., Suzuki H., Uemura H., McKay R., Ades S., Flechon A., Pieczonka C., Fernandes M.S., Hulstijn M., Lithio A., Nacerddine K., Agarwal N., CYCLONE 2 investigators. Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2025; 26(11): 1489-1500. doi: 10.1016/S1470-2045(25)00475-9.Fizazi K., Clarke N.W., De Santis M., Uemura H., Fay A.P., Karadurmus N., Kwiatkowski M., Alvarez-Fernandez C., Jiang S., Sotelo M., Parslow D., Oliveira N., Kwon T.G., Ye D., Boudewijns S., Danchaivijitr P., Rooney C., Gresty C., Yeste-Velasco M., Logan J., George D.J., CAPItello-281 Study Group. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026; 37(1): 53-68. doi: 10.1016/j.annonc.2025.10.004.Fizazi K., Clarke N.W., De Santis M., Uemura H., Fay A.P., Karadurmus N., Kwiatkowski M., Alvarez-Fernandez C., Jiang S., Sotelo M., Parslow D., Oliveira N., Kwon T.G., Ye D., Boudewijns S., Danchaivijitr P., Rooney C., Gresty C., Yeste-Velasco M., Logan J., George D.J., CAPItello-281 Study Group. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026; 37(1): 53-68. doi: 10.1016/j.annonc.2025.10.004.Danielak D., Krejcti T., Beranek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. 2022; 176: 106254. doi: 10.1016/j.ejps.2022.106254.Danielak D., Krejcti T., Beranek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. 2022; 176: 106254. doi: 10.1016/j.ejps.2022.106254.Juárez Soto A., Caballero Cobos R., Campanario Pérez R., Saiz Marenco R., Herrera Torres M., Gamaza Martínez R., Amores Bermúdez J. Abiraterone in castration resistant prostate cancer. Arch Esp Urol. 2018; 71(8): 651-63.Juárez Soto A., Caballero Cobos R., Campanario Pérez R., Saiz Marenco R., Herrera Torres M., Gamaza Martínez R., Amores Bermúdez J. Abiraterone in castration resistant prostate cancer. Arch Esp Urol. 2018; 71(8): 651-63.Singh P., Sinha A., Lama Tamang T.G., Chandra A.B., Huang Y.J. Abiraterone-Associated Fulminant Liver Failure. Am J Ther. 2018; 25(4): e505-e506. doi: 10.1097/MJT.0000000000000597.Singh P., Sinha A., Lama Tamang T.G., Chandra A.B., Huang Y.J. Abiraterone-Associated Fulminant Liver Failure. Am J Ther. 2018; 25(4): e505-e506. doi: 10.1097/MJT.0000000000000597.Decamps S., Lis R., Ekanayake P. Abiraterone-Induced Endocrinopathies. JCEM Case Rep. 2023; 1(2): luad039. doi: 10.1210/jcemcr/luad039.Decamps S., Lis R., Ekanayake P. Abiraterone-Induced Endocrinopathies. JCEM Case Rep. 2023; 1(2): luad039. doi: 10.1210/jcemcr/luad039.Lee H.Y., Chen H.L., Teoh J.Y., Chen T.C., Hao S.Y., Tsai H.Y., Huang W.H., Juan Y.S., Cheng H.M., Chang H.M. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 2021; 24(1): 244-52. doi: 10.1038/s41391-020-00275-3.Lee H.Y., Chen H.L., Teoh J.Y., Chen T.C., Hao S.Y., Tsai H.Y., Huang W.H., Juan Y.S., Cheng H.M., Chang H.M. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 2021; 24(1): 244-52. doi: 10.1038/s41391-020-00275-3.Danielak D., Krejčí T., Beránek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. 2022; 176: 106254. doi: 10.1016/j.ejps.2022.106254.Danielak D., Krejčí T., Beránek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci. 2022; 176: 106254. doi: 10.1016/j.ejps.2022.106254.Geboers S., Stappaerts J., Mols R., Snoeys J., Tack J., Annaert P., Augustijns P. The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man. J Pharm Sci. 2016; 105(9): 2974-81. doi: 10.1016/j.xphs.2016.03.008.Geboers S., Stappaerts J., Mols R., Snoeys J., Tack J., Annaert P., Augustijns P. The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man. J Pharm Sci. 2016; 105(9): 2974-81. doi: 10.1016/j.xphs.2016.03.008.Szmulewitz R.Z., Peer C.J., Ibraheem A., Martinez E., Kozloff M.F., Carthon B., Harvey R.D., Fishkin P., Yong W.P., Chiong E., Nabhan C., Karrison T., Figg W.D., Stadler W.M., Ratain M.J. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018; 36(14): 1389-95. doi: 10.1200/JCO.2017.76.4381.Szmulewitz R.Z., Peer C.J., Ibraheem A., Martinez E., Kozloff M.F., Carthon B., Harvey R.D., Fishkin P., Yong W.P., Chiong E., Nabhan C., Karrison T., Figg W.D., Stadler W.M., Ratain M.J. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018; 36(14): 1389-95. doi: 10.1200/JCO.2017.76.4381.Lu X., Dai T., Chen X., Wu B., Chen H., Wu J., Yu D., Ge H., Li J., Huang H., Fan T., Cheng L., Zhang X., Zhang X., Yao X., Wei J., Xu Z., Yang W., He C., Luo J., Guan L., Fu B., Wang Q., Chen X., Zhang Y., Shi B., Zheng B., Wang Y., Luo H., Chen G., Wang H., Wang Q., Ye D. A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer. BMC Med. 2025; 23(1): 271. doi: 10.1186/s12916-025-04053-7.Lu X., Dai T., Chen X., Wu B., Chen H., Wu J., Yu D., Ge H., Li J., Huang H., Fan T., Cheng L., Zhang X., Zhang X., Yao X., Wei J., Xu Z., Yang W., He C., Luo J., Guan L., Fu B., Wang Q., Chen X., Zhang Y., Shi B., Zheng B., Wang Y., Luo H., Chen G., Wang H., Wang Q., Ye D. A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer. BMC Med. 2025; 23(1): 271. doi: 10.1186/s12916-025-04053-7.Romero-Laorden N., Lozano R., Jayaram A., López-Campos F, Saez M.I., Montesa A., Gutierrez-Pecharoman A., Villatoro R., Herrera B., Correa R., Rosero A., Pacheco M.I., Garces T., Cendon Y., Nombela M.P., Van de Poll F., Grau G., Rivera L., López P.P., Cruz J.J., Lorente D., Attard G., Castro E., Olmos D. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer. 2018; 119(9): 1052-59. doi: 10.1038/s41416-018-0123-9.Romero-Laorden N., Lozano R., Jayaram A., López-Campos F, Saez M.I., Montesa A., Gutierrez-Pecharoman A., Villatoro R., Herrera B., Correa R., Rosero A., Pacheco M.I., Garces T., Cendon Y., Nombela M.P., Van de Poll F., Grau G., Rivera L., López P.P., Cruz J.J., Lorente D., Attard G., Castro E., Olmos D. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). Br J Cancer. 2018; 119(9): 1052-59. doi: 10.1038/s41416-018-0123-9.Adamo B., Bellet M., Paré L., Pascual T., Vidal M., Pérez Fidalgo J.A., Blanch S., Martinez N., Murillo L., Gómez-Pardo P., López-González A., Amillano K., Canes J., Galván P., González-Farré B., González X., Villagrasa P., Ciruelos E., Prat A. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Res. 2019; 21(1): 108. doi: 10.1186/s13058-019-1195-z.Adamo B., Bellet M., Paré L., Pascual T., Vidal M., Pérez Fidalgo J.A., Blanch S., Martinez N., Murillo L., Gómez-Pardo P., López-González A., Amillano K., Canes J., Galván P., González-Farré B., González X., Villagrasa P., Ciruelos E., Prat A. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Res. 2019; 21(1): 108. doi: 10.1186/s13058-019-1195-z.Zhang L., Zhou L., Shi Y., An X. Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study. Asian J Surg. 2024; 47(8): 3577-78. doi: 10.1016/j.asjsur.2024.03.149.Zhang L., Zhou L., Shi Y., An X. Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration-resistant prostate cancer: A retrospective, real-world study. Asian J Surg. 2024; 47(8): 3577-78. doi: 10.1016/j.asjsur.2024.03.149.Patel A., Tannock I.F, Sri vastava P., Biswas B., Gupta V G., Batra A., Bhethanabhotla S., Pramanik R., Mahindru S., Tilak T., Das C.K., Mehta P. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol. 2020; 6: 382-86. doi: 10.1200/JGO.19.00341.Patel A., Tannock I.F, Srivastava P., Biswas B., Gupta V G., Batra A., Bhethanabhotla S., Pramanik R., Mahindru S., Tilak T., Das C.K., Mehta P. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol. 2020; 6: 382-86. doi: 10.1200/JGO.19.00341.Peters N., Zameer M.Z., O'Reilly S. Low-Dose Abiraterone, a Rare European Commodity. JCO Glob Oncol. 2020; 6: 730. doi: 10.1200/GO.20.00106.Peters N., Zameer M.Z., O'Reilly S. Low-Dose Abiraterone, a Rare European Commodity. JCO Glob Oncol. 2020; 6: 730. doi: 10.1200/GO.20.00106.Lopes J.B., Sanches A.E., Dobbert B.M., Forner L., Homse Netto J.P., Fadul L., Guedes J.D., Fernandez F., Araujo D.V. Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer. JCO Glob Oncol. 2025; 11: e2500132. doi: 10.1200/GO-25-00132.Lopes J.B., Sanches A.E., Dobbert B.M., Forner L., Homse Netto J.P., Fadul L., Guedes J.D., Fernandez F., Araujo D.V. Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer. JCO Glob Oncol. 2025; 11: e2500132. doi: 10.1200/GO-25-00132.Jiang L., Wang J., Peng G., Zhang H., Fang J., Gao Y., Lou E., Liu Y., Ding W., Liu B., Mao Q., Jiang L., Liu A., Li X., Hu S., Ma Q., Zheng Y., Zhao Z., Shi X. A Super-Enhancer-Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration-Resistant Prostate Cancer. Adv Sci (Weinh). 2025; 12(31): e01284. doi: 10.1002/advs.202501284.Jiang L., Wang J., Peng G., Zhang H., Fang J., Gao Y., Lou E., Liu Y., Ding W., Liu B., Mao Q., Jiang L., Liu A., Li X., Hu S., Ma Q., Zheng Y., Zhao Z., Shi X. A Super-Enhancer-Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration-Resistant Prostate Cancer. Adv Sci (Weinh). 2025; 12(31): e01284. doi: 10.1002/advs.202501284.Xiong X., Qiu S., Yi X., Xu H., Lei H., Liao D., Bai S., Peng G., Wei Q., Ai J., Yang L. Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. Urol Oncol. 2022; 40(1): 4.e19-4.e28. doi: 10.1016/j.urolonc.2021.08.014.Xiong X., Qiu S., Yi X., Xu H., Lei H., Liao D., Bai S., Peng G., Wei Q., Ai J., Yang L. Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. Urol Oncol. 2022; 40(1): 4.e19-4.e28. doi: 10.1016/j.urolonc.2021.08.014.Markowski M.C., Shenderov E., Eisenberger M.A., Kachhap S., Pardoll D.M., Denmeade S.R., Antonarakis E.S. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate. 2020; 80(5): 407-11. doi: 10.1002/pros.23955.Markowski M.C., Shenderov E., Eisenberger M.A., Kachhap S., Pardoll D.M., Denmeade S.R., Antonarakis E.S. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate. 2020; 80(5): 407-11. doi: 10.1002/pros.23955.Mohammad O.S., Nyquist M.D., Schweizer M.T., Balk S.P., Corey E., Plymate S., Nelson P.S., Mostaghel E.A. Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions. Cancers (Basel). 2017; 9(12): 166. doi: 10.3390/can-cers9120166.Mohammad O.S., Nyquist M.D., Schweizer M.T., Balk S.P., Corey E., Plymate S., Nelson P.S., Mostaghel E.A. Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions. Cancers (Basel). 2017; 9(12): 166. doi: 10.3390/can-cers9120166.Roediger J., Hessenkemper W., Bartsch S., Manvelyan M., Huettner S.S., Liehr T., Esmaeili M., Foller S., Petersen I., Grimm M.O., Baniahmad A. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer. 2014; 13: 214. doi: 10.1186/1476-4598-13-214.Roediger J., Hessenkemper W., Bartsch S., Manvelyan M., Huettner S.S., Liehr T., Esmaeili M., Foller S., Petersen I., Grimm M.O., Baniahmad A. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Mol Cancer. 2014; 13: 214. doi: 10.1186/1476-4598-13-214.Teply B.A., Wang H., Luber B., Sullivan R., Rifkind I., Bruns A., Spitz A., DeCarli M., Sinibaldi V., Pratz C.F., Lu C., Silberstein J.L., Luo J., Schweizer M.T., Drake C.G., Carducci M.A., Paller C.J., Antonarakis E.S., Eisenberger M.A., Denmeade S.R. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018; 19(1): 76-86. doi: 10.1016/S1470-2045(17)30906-3.Teply B.A., Wang H., Luber B., Sullivan R., Rifkind I., Bruns A., Spitz A., DeCarli M., Sinibaldi V., Pratz C.F., Lu C., Silberstein J.L., Luo J., Schweizer M.T., Drake C.G., Carducci M.A., Paller C.J., Antonarakis E.S., Eisenberger M.A., Denmeade S.R. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018; 19(1): 76-86. doi: 10.1016/S1470-2045(17)30906-3.Schweizer M.T., Antonarakis E.S., Wang H., Ajiboye A.S., Spitz A., Cao H., Luo J., Haffner M.C., Yegnasubramanian S., Carducci M.A., Eisenberger M.A., Isaacs J.T., Denmeade S.R. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015; 7(269): 269ra2. doi: 10.1126/scitranslmed.3010563.Schweizer M.T., Antonarakis E.S., Wang H., Ajiboye A.S., Spitz A., Cao H., Luo J., Haffner M.C., Yegnasubramanian S., Carducci M.A., Eisenberger M.A., Isaacs J.T., Denmeade S.R. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015; 7(269): 269ra2. doi: 10.1126/scitranslmed.3010563.Schweizer M.T., Wang H., Luber B., Nadal R., Spitz A., Rosen D.M., Cao H., Antonarakis E.S., Eisenberger M.A., Carducci M.A., Paller C., Denmeade S.R. Bipolar androgen therapy for men with androgen ablation naive prostate cancer: Results from the phase II BATMAN study. Prostate. 2016; 76(13): 1218-26. doi: 10.1002/pros.23209.Schweizer M.T., Wang H., Luber B., Nadal R., Spitz A., Rosen D.M., Cao H., Antonarakis E.S., Eisenberger M.A., Carducci M.A., Paller C., Denmeade S.R. Bipolar androgen therapy for men with androgen ablation naive prostate cancer: Results from the phase II BATMAN study. Prostate. 2016; 76(13): 1218-26. doi: 10.1002/pros.23209.Sena L.A., Kumar R., Sanin D.E., Thompson E.A., Rosen D.M., Dalrymple S.L., Antony L., Yang Y., Gomes-Alexandre C., Hicks J.L., Jones T., Bowers K.A., Eskra J.N., Meyers J., Gupta A., Skaist A., Yegnasubramanian S., Luo J., Brennen W.N., Kachhap S.K., Antonarakis E.S., De Marzo A.M., Isaacs J.T., Markowski M.C., Denmeade S.R. Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC. J Clin Invest. 2022; 132(23): e162396. doi: 10.1172/JCI162396.Sena L.A., Kumar R., Sanin D.E., Thompson E.A., Rosen D.M., Dalrymple S.L., Antony L., Yang Y., Gomes-Alexandre C., Hicks J.L., Jones T., Bowers K.A., Eskra J.N., Meyers J., Gupta A., Skaist A., Yegnasubramanian S., Luo J., Brennen W.N., Kachhap S.K., Antonarakis E.S., De Marzo A.M., Isaacs J.T., Markowski M.C., Denmeade S.R. Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC. J Clin Invest. 2022; 132(23): e162396. doi: 10.1172/JCI162396.Denmeade S.R. Bipolar androgen therapy in the treatment of prostate cancer. Clin Adv Hematol Oncol. 2018; 16(6): 408-11.Denmeade S.R. Bipolar androgen therapy in the treatment of prostate cancer. Clin Adv Hematol Oncol. 2018; 16(6): 408-11.You X., Huang S., Wang X., Yi C., Gong N., Yu J., Xu C., Xiang Z. Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review. Front Endocrinol (Lausanne). 2023; 13: 1125838. doi: 10.3389/fendo.2022.1125838.You X., Huang S., Wang X., Yi C., Gong N., Yu J., Xu C., Xiang Z. Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review. Front Endocrinol (Lausanne). 2023; 13: 1125838. doi: 10.3389/fendo.2022.1125838.Kuzminac I.Z., NikolicA.R., SavicM.P., Ajdukovic J. J. Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective. Pharmaceutics. 2024; 16(11): 1401. doi: 10.3390/pharmaceutics16111401.Kuzminac I.Z., NikolicA.R., SavicM.P., Ajdukovic J. J. Abiraterone and Galeterone, Powerful Tools Against Prostate Cancer: Present and Perspective. Pharmaceutics. 2024; 16(11): 1401. doi: 10.3390/pharmaceutics16111401.Nurieva E.V, Britikova E.V., Sydoriuk A.V., Antonenko TA., Mamaeva A.V, Zefirov NA., Zazdravnykh A.V, Tafeenko VA., Bocharov E.V, Britikov V.V., Milaeva E.R., Zefirova O.N. New abiraterone analogue with atypical position of N-heterocyclic substituent: synthesis, crystal structure and CYP17A1/CYP3A4 binding affinity. Mendeleev Communications. 2026; 36(2): 138-41. doi: 10.71267/mencom.7900.Nurieva E.V, Britikova E.V., SydoriukA.V., Antonenko TA., Mamaeva A.V, ZefirovNA., ZazdravnykhA.V, Tafeenko VA., Bocharov E.V, Britikov V.V., Milaeva E.R., Zefirova O.N. New abiraterone analogue with atypical position of N-heterocyclic substituent: synthesis, crystal structure and CYP17A1/CYP3A4 binding affinity. Mendeleev Communications. 2026; 36(2): 138-41. doi: 10.71267/mencom.7900.Shpakovsky D.B., Berseneva D.A., Gracheva Yu.A., Antonenko T.A., Oprunenko Yu.F., Britikov V.V., Britikova E.V., Milaeva E.R. Synthesis and antiproliferative activity of novel organotin complexes bearing abiraterone drug moiety. Mendeleev Communications. 2024; 34(1): 22-24. doi: 10.1016/j.mencom.2024.01.007.Shpakovsky D.B., Berseneva D.A., Gracheva Yu.A., Antonenko T.A., Oprunenko Yu.F., Britikov V.V., Britikova E.V., Milaeva E.R. Synthesis and antiproliferative activity of novel organotin complexes bearing abiraterone drug moiety. Mendeleev Communications. 2024; 34(1): 22-24. doi: 10.1016/j.mencom.2024.01.007.Nurieva E.V., Kravtsova O.Yu., Sydoriuk A.V., Britikova E.V., Britikov V.V., Zefirov N.A., Milaeva E.R., Zefirova O.N. The homodimer approach to the design of a new long-acting depot prodrug of abiraterone. Mendeleev Communications. 2024; 34(4): 502-504. doi: 10.1016/j.mencom.2024.06.010.Nurieva E.V., Kravtsova O.Yu., Sydoriuk A.V., Britikova E.V., Britikov V.V., Zefirov N.A., Milaeva E.R., Zefirova O.N. The homodimer approach to the design of a new long-acting depot prodrug of abiraterone. Mendeleev Communications. 2024; 34(4): 502-504. doi: 10.1016/j.mencom.2024.06.010.Antonenko T.A., Gracheva Yu.A., Zazdravnykh A.V., Mazur D.M., Shpakovsky D.B., Lyssenko K.A., Milaeva E.R. Synthesis and antiproliferative activity of new copper, cobalt, and zinc complexes with abiraterone acetate. Russ J Coord Chem. 2023; 49(9): 612-21. doi: 10.1134/S1070328423600547.Antonenko T.A., Gracheva Yu.A., Zazdravnykh A.V., Mazur D.M., Shpakovsky D.B., Lyssenko K.A., Milaeva E.R. Synthesis and antiproliferative activity of new copper, cobalt, and zinc complexes with abiraterone acetate. Russ J Coord Chem. 2023; 49(9): 612-21. doi: 10.1134/S1070328423600547.Eremeev R.O., Dubinina T., Burtsev I.D., Markova A.A., Borisova N.E., Ivanova M.M., Belousov M.S., Kosov A.D., Khabibullin V.R., Proskurnin M.A., Kuzmin V.A., Milaeva E.R. Novel subporphyrazine-drug hybrid photosensitizers containing diclofenac and abiraterone: synthesis, photophysical properties and photodynamic activity in vitro. Dyes and Pigments. 2025; 241: 112868. doi: 10.1016/j.dyepig.2025.112868.Eremeev R.O., Dubinina T., Burtsev I.D., Markova A.A., Borisova N.E., Ivanova M.M., Belousov M.S., Kosov A.D., Khabibullin V.R., Proskurnin M.A., Kuzmin V.A., Milaeva E.R. Novel subporphyrazine-drug hybrid photosensitizers containing diclofenac and abiraterone: synthesis, photophysical properties and photodynamic activity in vitro. Dyes and Pigments. 2025; 241: 112868. doi: 10.1016/j.dyepig.2025.112868.Zhu N., Meng S., Mao L., Rong Y., Wang X., Liu Y., Hong G., Zhou K., Li B., Liu T. Amino polycarboxylic acids-modified abiraterone derivatives as potential injectable anti-prostate cancer agents. Bioorg Chem. 2024; 153: 107824. doi: 10.1016/j.bioorg.2024.107824.Zhu N., Meng S., Mao L., Rong Y., Wang X., Liu Y., Hong G., Zhou K., Li B., Liu T. Amino polycarboxylic acids-modified abiraterone derivatives as potential injectable anti-prostate cancer agents. Bioorg Chem. 2024; 153: 107824. doi: 10.1016/j.bioorg.2024.107824.

The authors declare that there are no conflicts of interest present.